D3L-001

N/A

Report date: 2023/09/01 17:50:27

Base Information

Drug NameD3L-001
Drug Alias NameD3L-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsCluster of differentiation 47Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesD3 Bio (Wuxi) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesD3 Bio (Wuxi) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A